Phase I dose escalation study of lestaurtinib in patients with myelofibrosis
Elizabeth O. Hexner(University of Pennsylvania), Robert S. Hoffman(New York City Department of Health and Mental Hygiene), Heike L. Pahl(University Medical Center Freiburg), James Siuty(Tisch Hospital), Attilio Orazi(Texas Tech University), Josef T. Prchal(Huntsman Cancer Institute), Vesna Najfeld, Maria R. Baer(University of Maryland, Baltimore), Rona Singer Weinberg(University of North Carolina at Chapel Hill), Erin P. Demakos(Tisch Hospital), D Leibowitz(Sutter Health), Grace R. Jeschke(Georgetown University), Jill Kleczko(Tisch Hospital), John Mascarenhas(Tisch Hospital), Leah Price(Cwm Taf University Health Board), Ellen K. Ritchie(Cornell University), Roberto Marchioli(IQVIA (United Kingdom)), Crystal Miller(Mount Sinai Medical Center), Lewis R. Silverman(Icahn School of Medicine at Mount Sinai), Judith D. Goldberg(New York University), Titiksha Basu(University Medical Center Freiburg), Gail J. Roboz(Cornell University)
Cited by 34
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k